10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



# STAT1 antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI10505

#### **Product Information**

Application WB Primary Accession P42224

Other Accession <u>NM\_007315</u>, <u>NP\_009330</u>

**Reactivity** Human, Mouse, Rat, Pig, Dog, Bovine **Predicted** Human, Mouse, Rat, Pig, Dog, Bovine

Host Rabbit
Clonality Polyclonal
Calculated MW 87335

### **Additional Information**

**Gene ID** 6772

Alias Symbol DKFZp686B04100, ISGF-3, STAT91, CANDF7

Other Names Signal transducer and activator of transcription 1-alpha/beta, Transcription

factor ISGF-3 components p91/p84, STAT1

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

**Reconstitution & Storage** Add 50 ul of distilled water. Final anti-STAT1 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

**Precautions** STAT1 antibody - N-terminal region is for research use only and not for use in

diagnostic or therapeutic procedures.

### **Protein Information**

Name STAT1

**Function** Signal transducer and transcription activator that mediates cellular

responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and

other growth factors (PubMed:<u>12764129</u>, PubMed:<u>12855578</u>, PubMed:<u>15322115</u>, PubMed:<u>23940278</u>, PubMed:<u>34508746</u>,


PubMed:<u>35568036</u>, PubMed:<u>9724754</u>). Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus (PubMed:<u>28753426</u>, PubMed:<u>35568036</u>). ISGF3 binds to

the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state (PubMed: <u>28753426</u>, PubMed: <u>35568036</u>). In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated (PubMed:26479788). It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state (PubMed:8156998). Becomes activated in response to KITLG/SCF and KIT signaling (PubMed: 15526160). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed: 19088846). Following bacterial lipopolysaccharide (LPS)-induced TLR4 endocytosis, phosphorylated at Thr-749 by IKBKB which promotes binding of STAT1 to the 5'-TTTGAGGC-3' sequence in the ARID5A promoter, resulting in transcriptional activation of ARID5A and subsequent ARID5A-mediated stabilization of IL6 (PubMed: 32209697). Phosphorylation at Thr-749 also promotes binding of STAT1 to the 5'-TTTGAGTC-3' sequence in the IL12B promoter and activation of IL12B transcription (PubMed:32209697). Involved in food tolerance in small intestine: associates with the Gasdermin-D, p13 cleavage product (13 kDa GSDMD) and promotes transcription of CIITA, inducing type 1 regulatory T (Tr1) cells in upper small intestine (By similarity).

#### **Cellular Location**

Cytoplasm. Nucleus Note=Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to IFN-gamma and signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4 (PubMed:15322115). Monomethylation at Lys- 525 is required for phosphorylation at Tyr-701 and translocation into the nucleus (PubMed:28753426). Translocates into the nucleus in response to interferon-beta stimulation (PubMed:26479788)

## **Images**



WB Suggested Anti-STAT1 Antibody Titration: .2-1 ug/ml

ELISA Titer: 1:625

Positive Control: recombinant STAT1 protein

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.